National Cancer Institute (NCI)’s Post

I'm looking forward to the discussion on tomorrow’s post about how cannabis can help prevent cancer by inhibiting angiogenesis! This is crucial information that isn't openly discussed yet, and I'm excited to bring it to light. By understanding the role of cannabis in cancer prevention, we can make more informed health choices. Don’t miss out on this valuable insight—subscribe now for first access: https://lnkd.in/gFNA26fZ 🌿✨ #CancerPrevention #CannabisScience #MedicalResearch #HealthEducation #StayInformed For anyone concerned about building a tolerance to cannabis, I hope this sheds some light on the benefits. Increased cannabis use means more inhibition of angiogenesis. Read on to see what I mean!

This poster demonstrates how digital clinical measures can be used in drug development to address the unmet needs in Alzheimer’s disease. https://hubs.la/Q02jlV1V0 #clinicalresearch #clinicaltrials #digitalendpoints #digitalbiomarkers

Oral drug regimes, delivered in community settings, have the ability to reach wider sections of society. The FDA continue to take diversity and inclusion seriously. Latest guidance: https://lnkd.in/eT5AhNTP CellCentric is developing a new oral treatment for multiple myeloma. While cell and antibody-based therapies have brought great progress for patients, they can be complex to administer, and not suitable for many. There is a growing need for complementary approaches, able to be administered in community settings. Despite significant gains in recent times, 75% of people diagnosed with multiple myeloma still die of the disease. There remains a real need for continued progress. #multiplemyeloma Will West Debbie Haynes Tomasz Knurowski Kris Frese Karen Clegg

Hinge Bio raises $30M Series A' to advance next-generation therapies to treat autoimmune disorders and other high unmet need indications via its GEM-DIMER platform! #JPM2025 #autoimmune

1. The European Medicines Agency has approved Lecanemab, the first drug targeting the root cause of Alzheimer's disease. 2. The drug offers hope despite limited efficacy and potential side effects. 3. Lecanemab delays Alzheimer's symptoms by an average of five months in trial participants. 4. The drug works by removing beta-amyloid plaques that damage nerve cells in the brain. 5. There is a growing development of antibody therapies and blood tests for early detection of Alzheimer's. 6. Concerns exist regarding the side effects, including brain hemorrhages in some patients. 7. Access to antibody therapies is limited, primarily benefiting patients in early stages of Alzheimer's. 8. The medical community is cautious about long-term use and the implications of sustained antibody treatments.

InMed's INM-901 is a drug candidate demonstrating a multi-factorial approach to treating #Alzheimers disease. Promising studies demonstrate INM-901’s neuroprotective effects and an ability to extend neurite length, signifying improved neuronal function - a unique therapeutic effect not shown in any current #AlzheimersDisease treatments. Watch this video presentation by InMed’s CEO, Eric A. Adams, as he shares data on the unique pharmacological effects of INM-901: https://ow.ly/5qYV50Upy4J $INM

🧠 Big news in the fight against Alzheimer's! 💊 Today, the FDA’s eleven-person advisory committee unanimously voted that Eli Lilly and Company’s anti-amyloid Alzheimer's #drug #donanemab was effective, and that the benefits of the drug outweigh the risks for people with the earliest stages of #Alzheimers disease. The agency is expected to make their final decision on approving the drug in the next few weeks. Read the full article from Being Patient's Simon Spichak👇 #AlzheimersDrugs #AlzheimersDisease #AlzheimersAwareness #BrainHealth

A new Alzheimer's drug may hit the market soon. Here's what you need to know: I spent yesterday watching the FDA #AdComm for Eli Lilly and Company's anti-amyloid drug #donanemab. While the eleven-person committee unanimously recommended the drug for approval there were still some lingering questions. The FDA will make their final decision in the coming weeks. Donanemab doesn't stop Alzheimer's disease, the evidence from the Phase 3 clinical trial suggests that it might slow its progression a bit. The trial enrolled patients based on tau levels, and excluded those with no or very low levels of tau in the brain. People with medium levels of tau seemed to benefit most from the treatment. Advisory committee members argued it wouldn't be practical or useful to require people to take a tau PET scan before being prescribed the drug. Unlike Leqembi, patients who are on the drug stop receiving it once the #amyloid plaques in the brain are cleared. In practice, this means doctors need to figure out when to time an amyloid PET scan to measure if these plaques have been cleared. Some of the members on the committee where uncertain over how much patients with two copies of the #APOE4 gene might benefit from the drug. There's also still uncertainty over why people taking the drug seemed to experience more brain shrinkage than those on placebo, even if they experienced a statistically significant reduction in symptoms and amyloid. Read more Being Patient

NEW CYCLIBTOOL - NOW AVAILABLE   Find out how artificial intelligence can help you detect interactions between iCDK4/6 and other drugs in www.cyclibtool.org   💻 CYCLIBTOOL is designed to inform healthcare professionals about potential drug interactions (DDIs), their mechanisms of action, and most importantly, to provide positive lists of medications considered safe when administered in combination with CDK4/6 inhibitors.   💥Following the excellent reception of Cyclibtool worldwide by the medical and healthcare community, in 2023 we began preparing a new version. With more medications, multilingual support, and in a format more in line with current times.   Meritxell Bellet #beSOLTI #breastcancer #cancerdemama

Brilliant! Thanks once again to Kevin McFarthing, Simon Stott et al. for the 2024 update to Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline. Not only is it an indispensable guide for anyone wanting to gain an overview of the clinical trial landscape in Parkinson's disease but it also includes something every science article should have, a Plain Language Summary at the top. Click the link below for the full thing.... https://lnkd.in/gQ_Z-cWV